Company news

Ensysce Biosciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 Studies

September 13, 2023

Ensysce Presents "A New Generation of Safer Pain Treatments"

September 6, 2023

Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific Symposium

August 13, 2023

Ensysce Biosciences Reports Second Quarter 2023 Financial Results

August 10, 2023

Ensysce Biosciences Announces IRB Approval of Key Study Protocol

August 7, 2023

Ensysce Biosciences Announces Engagement of Alacrita Consulting

July 25, 2023

Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo

June 26, 2023

Ensysce Biosciences Releases Updated Investor Presentation Available Via Investor Relations Website

June 6, 2023

Ensysce Biosciences Reports First Quarter 2023 Financial Results

May 14, 2023

Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering

May 11, 2023

Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering

May 9, 2023

Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection

May 8, 2023

Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614

April 2, 2023

Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results

March 29, 2023

Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study

March 21, 2023

Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock

February 27, 2023

Ensysce Biosciences Provides Corporate Update

February 22, 2023

Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting

February 13, 2023

Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules

February 6, 2023

Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering

February 2, 2023

Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock

January 31, 2023

Ensysce Biosciences Announces Initiation of Final Stage of Groundbreaking Opioid Overdose Protection Phase 1 Study

January 24, 2023

Ensysce Biosciences Issues 2023 Shareholder Letter

January 10, 2023

Ensysce Biosciences Announces Successful Completion of Clinical Portion of Oral Human Abuse Potential Trial

January 3, 2023

Ensysce Biosciences Announces Data from PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection

December 18, 2022

Ensysce Biosciences Announces Pricing of $4.1 Million Public Offering

December 6, 2022

Ensysce Biosciences Announces Completion of Clinical Portion of Overdose Protection Trial PF614-MPAR-101-Part A

December 4, 2022

Ensysce Biosciences Reports Third Quarter 2022 Financial Results

November 13, 2022

Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614

November 13, 2022

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

October 30, 2022

Ensysce Biosciences Announces First Subjects Dosed in Second Human Abuse Potential Study

October 27, 2022

Ensysce Biosciences, Inc. Announces Participation in LD Micro Main Event XV Conference

October 11, 2022

Ensysce Biosciences Announces Initiation of Second Human Abuse Potential Study, Being Conducted by DVCR

September 21, 2022

Ensysce Biosciences Announces Results of Special Meeting of Stockholders

September 7, 2022

Ensysce Biosciences Reminds Shareholders to Vote at Upcoming Special Meeting

September 5, 2022

Ensysce Biosciences and Quotient Sciences Announce a Partnership on the Development and Clinical Testing of Ensysce's PF614-MPAR, a Novel Opioid Designed to Prevent Abuse and Overdose

August 30, 2022

Ensysce Biosciences, Inc. Announces Participation in Upcoming Conferences

August 23, 2022

Ensysce Biosciences Announces Completion of Clinical Portion of Human Abuse Potential Trial PF614-103

August 22, 2022

Ensysce Biosciences Provides Business Update and Reports Second Quarter 2022 Financial Results

August 10, 2022

Ensysce Biosciences Announces Completion of $8 Million Convertible Note Financing

August 8, 2022

Ensysce Biosciences Announces Positive Bioequivalence (BE) Study Data of Novel "TAAP" Opioid PF614 and Provides Timing of Corporate Update Call

July 26, 2022

Ensysce Biosciences Announces Initial Patients Dosed of First Human Abuse Potential Study

July 12, 2022

Ensysce Biosciences Secures $8 Million Convertible Note Financing

June 30, 2022

Ensysce Biosciences Receives Notice of Award for 4th Year of Funding for Its Multi-Pill Abuse Resistance (MPAR(TM)) Platform

June 26, 2022

Ensysce Biosciences Reminds Shareholders to Vote At Upcoming 2022 Virtual Annual Shareholder Meeting

June 20, 2022

Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

May 22, 2022

Ensysce Biosciences Provides Business Update and Reports First Quarter 2022 Financial Results

May 11, 2022

Ensysce Biosciences Releases 2021 Annual Shareholder Letter

May 4, 2022

Ensysce Biosciences Announces New Clinical Results from Trials PF614-102 and PF614-MPAR-101

May 4, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 8 decks. Every deck is listed under its year.